Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announces the closure of the transaction with Upsher-Smith Laboratories, LLC (Upsher-Smith), pursuant to the satisfactory completion of all customary closing conditions including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act), as amended.
Under the agreement Dr. Reddy's sold its US and select territory rights for ZEMBRACE® SYMTOUCH® (sumatriptan injection) 3 mg and TOSYMRA™ (sumatriptan nasal spray) 10 mg, which were commercialized through its wholly owned subsidiary, Promius Pharma, LLC.
Shares of DR.REDDY's LABORATORIES LTD. was last trading in BSE at Rs.2619 as compared to the previous close of Rs. 2655.5. The total number of shares traded during the day was 12221 in over 922 trades.
The stock hit an intraday high of Rs. 2679.55 and intraday low of 2605.45. The net turnover during the day was Rs. 32227734.